NeuroMetrix, Inc.
62 Fourth Avenue
Waltham
Massachusetts
02451
United States
Tel: 781-890-9989
Fax: 781-890-1556
Website: http://www.neurometrix.com/
Email: info@neurometrix.com
432 articles about NeuroMetrix, Inc.
-
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2021 Financial Results Conference Call
1/20/2022
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 fourth quarter and full year financial results before the opening of the market on January 27, 2022.
-
NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN) with its Wearable Neurostimulation Technology
1/18/2022
NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell® technology has received Breakthrough Designation from the U.S. Food and Drug Administration (FDA) for reducing moderate to severe symptoms of chemotherapy induced peripheral neuropathy that have persisted for at least 6-months following the end of chemotherapy.
-
NeuroMetrix Names Strategic Growth Executive, Brandi Damkier, as Vice President, Clinical Partnerships
1/10/2022
NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has appointed Brandi Damkier as Vice President, Clinical Partnerships.
-
NeuroMetrix to Present at H.C. Wainwright BioConnect Conference 2022
1/5/2022
NeuroMetrix, Inc. announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, will be presenting at the H.C. Wainwright BioConnect Conference to be held virtually on January 10-13, 2022.
-
NeuroMetrix Reports Q3 2021 Financial Results
10/21/2021
NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended September 30, 2021.
-
NeuroMetrix Names Strategic Growth Executive, Susan M. Bell, RN, BN, as Senior Vice President of Population Health & Value Based Care
10/20/2021
NeuroMetrix, Inc. announced that it has appointed Susan M. Bell as Senior Vice President, Population Health & Value Based Care.
-
NeuroMetrix, Inc. Announces Date for Third Quarter 2021 Financial Results Conference Call
10/14/2021
NeuroMetrix, Inc. announced that it plans to issue its 2021 third quarter financial results before the opening of the market on October 21, 2021.
-
NeuroMetrix Announces Submission of FDA De Novo Request for Treatment of Fibromyalgia Symptoms with the Quell® Wearable Neuromodulation Device
10/6/2021
NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has submitted a De Novo request to the U.S. Food and Drug Administration (FDA) for Quell as a prescription treatment for the symptoms of fibromyalgia in adults.
-
NeuroMetrix Announces Participation in the Center to Stream Healthcare In Place (C2SHIP) as an Industry Partner
10/5/2021
NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has joined the Center to Stream Healthcare In Place (C2SHIP) as an industry partner.
-
NeuroMetrix Announces Peer-Reviewed Publication of a Randomized Controlled Trial of its Wearable Neurostimulation Technology for Treatment of Fibromyalgia
7/26/2021
NeuroMetrix, Inc. (Nasdaq: NURO) today announced a publication titled “Effects of Wearable Transcutaneous Electrical Nerve Stimulation on Fibromyalgia: A Randomized Controlled Trial" in the Journal of Pain Research.
-
NeuroMetrix Reports Q2 2021 Financial Results
7/22/2021
NeuroMetrix, Inc. reported financial and business highlights for the quarter ended June 30, 2021.
-
The U.S. Food and Drug Administration has recently granted Breakthrough Device Designation to two medical device companies, with California-based healthcare tech company Endologix leading the mix.
-
NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Fibromyalgia with its Wearable Neurostimulation Technology
7/20/2021
NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell® device has received Breakthrough Designation from the U.S. Food and Drug Administration (FDA) for treating the symptoms of fibromyalgia in adults.
-
NeuroMetrix, Inc. Announces Date for Second Quarter 2021 Financial Results Conference Call
7/15/2021
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 second quarter financial results before the opening of the market on July 22, 2021.
-
NeuroMetrix Reports that Quell® Technology is to be Evaluated for Neuromyelitis Optica Spectrum Disorder (NMOSD) in a Randomized Controlled Trial
6/15/2021
NeuroMetrix, Inc. (Nasdaq: NURO) today announced that Quell technology will be used in a double-blinded, randomized, sham-controlled trial to determine whether transcutaneous electrical nerve stimulation (TENS) is an effective, acceptable and feasible method of pain relief in patients with NMOSD.
-
NeuroMetrix Reports Q1 2021 Financial Results
4/22/2021
NeuroMetrix, Inc. reported financial and business highlights for the quarter ended March 31, 2021.
-
NeuroMetrix, Inc. Announces Date for First Quarter 2021 Financial Results Conference Call
4/15/2021
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 first quarter financial results before the opening of the market on April 22, 2021. The Company will host a conference call at 8:00 a.m., Eastern Time on April 22, 2021 to discuss its financial results as well as business developments affecting the Company.
-
NeuroMetrix Reports Q4 and Full Year 2020 Financial Results
1/28/2021
NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and year ended December 31, 2020. The Company is focused on the development and global commercialization of non-invasive medical devices for the diagnosis and treatment of disorders involving the nervous system.
-
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2020 Financial Results Conference Call
1/22/2021
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2020 fourth quarter and full year financial results before the opening of the market on January 28, 2021. The Company will host a conference call at 8:00 a.m., Eastern Time on January 28, 2021 to discuss its financial results as well as business developments affecting the Company. The conference call may be accessed in the United States by dialing 844-787-0799 and usin
-
NeuroMetrix Reports Q3 2020 Financial Results
10/22/2020
NeuroMetrix, Inc. reported financial and business highlights for the quarter ended September 30, 2020.